Author Archives: Kara Elam

Corbus Pharmaceuticals Granted Fast Track Status for Investigational Drug Resunab(TM) to Treat Systemic Sclerosis

This week, Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced that Resunab™, has been granted Fast Track status for the clinical investigation of  by the U.S. Food and Drug Administration (FDA) for the treatment of systemic sclerosis…

Study Findings Show IPF Methods For Predicting Mortality Also Work For SSc-ILD

Recently, a group of researchers from University of British Columbia in Vancouver, Canada released study results in which they found that mortality risk prediction models used to clinically assess the 1-year survival rate for patients with idiopathic pulmonary fibrosis (IPF), could also be utilized to accurately predict short-term mortality in patients…

Researchers Evaluate the Effect of Ambrisentan on Digital Blood Flow in Patients with Systemic Sclerosis using Laser Doppler Perfusion Imaging

Researchers from the Hunter Holmes McGuire VA Medical Center, Richmond, VA, and the Department of Rheumatic and Immunologic Diseases, Orthopedics and Rheumatology Institute, Cleveland Clinic, OH, have recently released results from a clinical trial that evaluated the use of ambrisentan, a selective endothelin type A receptor antagonist,…

Study Suggests Optimal Systolic Pulmonary Arterial Pressure May Increase Systemic Scleroderma Patients’ Survival Time

A multi-national team of researchers attempting to find precise clinical indicators that would increase post-diagnosis survival times among patients living with systemic scleroderma (SSc), have recently published a study with promising conclusions.  The study consisted of patients previously diagnosed with SSc from the European League Against Rheumatism Scleroderma…